Fresenius Medical Care's Guidance Is Likely to Disappoint -- Market Talk

Dow Jones

Feb 24

0758 GMT - Fresenius Medical Care's guidance for 2026 is likely to disappoint as it implies the company is facing additional headwinds that will offset extra cost savings, analysts at Jefferies say. The German dialysis specialist forecast broadly flat revenue in 2026, and adjusted operating profit ranging from a mid-single-percentage digit rise to a fall of the same proportion. In light of expected savings of 250 million euros from an efficiency program, this points to intensifying headwinds elsewhere, Jefferies says in a research note. Moreover, Fresenius Medical Care reiterated its 2030 profitability guidance despite raising its 2027 savings target, the analysts say. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

February 24, 2026 02:59 ET (07:59 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2613798738"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613798738\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613798738?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 15:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613798738","market":"sg","top_or_hot":-1,"title":"Fresenius Medical Care's Guidance Is Likely to Disappoint -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0758 GMT - Fresenius Medical Care's guidance for 2026 is likely to disappoint as it implies the company is facing additional headwinds that will offset extra cost savings, analysts at Jefferies say. The German dialysis specialist forecast broadly flat revenue in 2026, and adjusted operating profit ranging from a mid-single-percentage digit rise to a fall of the same proportion. In light of expected savings of 250 million euros from an efficiency program, this points to intensifying headwinds elsewhere, Jefferies says in a research note. Moreover, Fresenius Medical Care reiterated its 2030 profitability guidance despite raising its 2027 savings target, the analysts say. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 24, 2026 02:59 ET (07:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fresenius Medical Care's Guidance Is Likely to Disappoint -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFresenius Medical Care's Guidance Is Likely to Disappoint -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-24 15:59</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0758 GMT - Fresenius Medical Care's guidance for 2026 is likely to disappoint as it implies the company is facing additional headwinds that will offset extra cost savings, analysts at Jefferies say. The German dialysis specialist forecast broadly flat revenue in 2026, and adjusted operating profit ranging from a mid-single-percentage digit rise to a fall of the same proportion. In light of expected savings of 250 million euros from an efficiency program, this points to intensifying headwinds elsewhere, Jefferies says in a research note. Moreover, Fresenius Medical Care reiterated its 2030 profitability guidance despite raising its 2027 savings target, the analysts say. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 24, 2026 02:59 ET (07:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FMS","symbol_name":"费森尤斯医疗","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2613798738","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613798738","pubTimestamp":1771919940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0758 GMT - Fresenius Medical Care's guidance for 2026 is likely to disappoint as it implies the company is facing additional headwinds that will offset extra cost savings, analysts at Jefferies say. The German dialysis specialist forecast broadly flat revenue in 2026, and adjusted operating profit ranging from a mid-single-percentage digit rise to a fall of the same proportion. In light of expected savings of 250 million euros from an efficiency program, this points to intensifying headwinds elsewhere, Jefferies says in a research note. Moreover, Fresenius Medical Care reiterated its 2030 profitability guidance despite raising its 2027 savings target, the analysts say. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FMS":"费森尤斯医疗","BK4196":"保健护理服务"},"translate_title":"费森尤斯医疗的指引可能会令人失望——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FMS":0.9},"content_text":"0758 GMT - Fresenius Medical Care's guidance for 2026 is likely to disappoint as it implies the company is facing additional headwinds that will offset extra cost savings, analysts at Jefferies say. The German dialysis specialist forecast broadly flat revenue in 2026, and adjusted operating profit ranging from a mid-single-percentage digit rise to a fall of the same proportion. In light of expected savings of 250 million euros from an efficiency program, this points to intensifying headwinds elsewhere, Jefferies says in a research note. Moreover, Fresenius Medical Care reiterated its 2030 profitability guidance despite raising its 2027 savings target, the analysts say. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2026 02:59 ET (07:59 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}